The pso Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the pso Hub cannot guarantee the accuracy of translated content. The pso and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The PsOPsA Hub is supported by educational grants. All educational content is developed independently by SES in collaboration with our expert steering committee, with no input or influence from financial supporters. We would like to express our gratitude to the following companies for their support: • UCB: For website development, launch, and ongoing maintenance. • UCB: For educational content and news updates.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View pso content recommended for you
Efficacy and safety of JNJ-77242113 in patients with moderate-to-severe psoriasis: Long-term extension FRONTIER-2 trial
|
In the phase IIb FRONTIER-1 trial (NCT05223868), JNJ-77242113, an oral IL-23 inhibitor, improved response rates vs placebo at Week 16 in patients with moderate-to-severe plaque psoriasis.1 The FRONTIER-2 trial (NCT05364554) assessed the safety and efficacy of JNJ-77242113 through to Week 52 in 227 patients who completed FRONTIER-1.1 Results from this trial were published in the Journal of the American Academy of Dermatology by Ferris et al.1 |
| Key learnings |
| At Week 52, 49%, 58%, 70%, 65%, 76%, and 66% of patients achieved a PASI 75 response in 25 mg QD, 25 mg BID, 50 mg QD, 100 mg QD, 100 mg BID, and placebo→100 mg QD groups, respectively. |
| The proportion of patients achieving PASI 90, PASI 100, IGA 0/1, and IGA 0 responses at Week 16 were generally maintained through Week 52, with the highest response rates in the higher dose groups. |
| Improvements in PRO measures at Week 16 were maintained through Week 52, and no new safety signals were observed. |
| Results from this trial demonstrate that the improvements in clinical and PRO measures with JNJ-77242113 at Week 16 were durable through Week 52 with no new safety signals, and patients switching from placebo to JNJ-77242113 100 mg QD experienced rapid improvements in response rates. Abbreviations: MDA, minimal disease activity; PsA, psoriatic arthritis. |
Abbreviations: BID, twice daily; IGA, Investigator’s Global Assessment; IL, interleukin; LTE, long-term extension; PASI, Psoriasis Area and Severity Index; PRO, patient-reported outcomes; QD, once daily.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
